Related Experiment Videos
Somatostatin receptors in nasopharyngeal carcinoma
Kwok Seng Loh1, Beatrice Waser, L K S Tan
1Department of Otolaryngology, Head and Neck Tumour Clinic, National University Hospital, Singapore.
Abstract:
Somatostatin receptors (SS-Rs) are expressed in neuroendocrine tumour tissues where they can be targetted for diagnosis and therapy. This study investigated the presence of SS-Rs in nasopharyngeal carcinoma (NPC), a common cancer in South-East Asia. Nasopharynx biopsy specimens were obtained from 12 NPC patients and 5 patients without tumours. Somatostatin receptor autoradiography was performed using (125)I-labelled [Tyr(3)]-octreotide and (125)I-labelled [Leu(8), DTrp(22), Tyr(25)]-somatostatin-28 as radioligands. Of the 12 NPC samples 9 showed moderate to high expression of SS-Rs. These were of the sst(2) type, based on the rank order of potency of subtype-selective analogues. The 5 non-neoplastic samples, consisting primarily of granulomatous tissue, did not express measurable amounts of SS-Rs. This study demonstrates for the first time the presence of type 2 SS-R in NPC. These receptors may play a role in the management of NPC, as is the case for other somatostatin-expressing tumours.
Insights
This study found that somatostatin receptors (SS-Rs) are present in most nasopharyngeal carcinoma (NPC) tumors. This discovery suggests SS-Rs could be a target for future NPC diagnosis and therapy.
Area of Science:
- Oncology
- Endocrinology
- Molecular Imaging
Background:
- Somatostatin receptors (SS-Rs) are crucial targets in neuroendocrine tumor diagnosis and therapy.
- Nasopharyngeal carcinoma (NPC) is a prevalent cancer in Southeast Asia, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate the expression of somatostatin receptors (SS-Rs) in nasopharyngeal carcinoma (NPC) tissues.
- To determine the subtype of SS-Rs present in NPC.
Main Methods:
- Utilized somatostatin receptor autoradiography on biopsy specimens from 12 NPC patients and 5 controls.
- Employed (125)I-labelled [Tyr(3)]-octreotide and (125)I-labelled [Leu(8), DTrp(22), Tyr(25)]-somatostatin-28 as radioligands.
Main Results:
- Demonstrated moderate to high expression of SS-Rs in 9 out of 12 NPC samples.
- Identified the expressed SS-Rs as predominantly the sst(2) subtype.
- Confirmed absence of measurable SS-Rs in non-neoplastic nasopharyngeal tissues.
Conclusions:
- This research provides the first evidence of type 2 somatostatin receptor expression in nasopharyngeal carcinoma.
- The presence of sst(2) receptors in NPC suggests their potential utility in diagnostic imaging and therapeutic interventions for this cancer.